Why insider trading matters?

Numerous studies have examined whether there is evidence that U.S. insiders systematically trade on private information despite the legal deterrence. The consensus appears to be that insider purchases (but not sales) tend to be followed by positive abnormal stock price performance, particularly for small growth stocks.

- Prof. B. Espen Eckbo, Dartmouth College
Aimmune Therapeutics, Inc. (AIMT)
Sector: Healthcare; Industry: Biotechnology

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-03-10 Dallas Jayson Donald Alexander President and CEO Buy 2,665 $18.74 $49,934 No
2018-11-19 Dallas Jayson Donald Alexander President and CEO Buy 3,650 $27.56 $100,587 No

Insider Smart

CEDAR FAIR L.P. (FUN) - Another crash victim, Cedar Fair L.P. took a deep dive from $54 to $13, insiders were confidence and eagerly jumped in around $27. With insiders on your side, this would be an easy add and hold to get your cost under $20. Stock is about to breach $40 in the coming weeks.

Insider Smart

Altimmune, Inc. (ALT) - Venrock Healthcare Capital Partners III, L.P., 10%-owner of ALT bought 1.3M shares in late May then added another 1.5M shares in June with an averaged ~$8 per share. 10 days after the accumulation, ALT price jumped to $10.